GHO Capital Acquires U.K.-based Quotient Clinical
Quotient Clinical is based in Nottingham, U.K., where formulation development, real-time Good Manufacturing Practice services, and early clinical trials are performed at the same facility.
Quotient Clinical, a provider of early stage and drug development services, has been acquired by healthcare investor GHO Capital.
Quotient Clinical is based in Nottingham, U.K., where formulation development, real-time Good Manufacturing Practice services, and early clinical trials are performed at the same facility. It employs over 280 staff and offers a range of support services, from study set-up to data analysis and reporting. Over 75% of its customers are in the U.S. or mainland Europe.
“We are delighted to be partnering with GHO Capital for the next phase of our growth,” said Mark Egerton, Chief Executive Officer of Quotient Clinical. “In the past few years, we have proven the benefits of Translational Pharmaceutics (the company’s own platform), and its adoption by an ever increasing number of customers continues to drive our business growth. Partnering with GHO Capital, we will now work to expand our differentiated service portfolio and extend our operational footprint internationally.”
Read the full release.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
